New Composition Patent Provides Additional Protection for Safe Osteoarthritis Prescription Product
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Primus Pharmaceuticals, Inc. announces the issuance of a new composition of matter patent for Limbrel, the first prescription medical food product to safely meet the distinctive nutritional requirements of patients with osteoarthritis (OA). U.S. Patent #7,514,469 was recently issued by the U.S. Patent and Trademark Office.
Limbrel contains flavocoxid, a proprietary composition of natural flavonoid ingredients from the plant sources of Scutellaria baicalensis and Acacia catechu that meet the FDA strict safety standard of Generally Recognized As Safe (GRAS). Under this new composition patent, allowable claims for Limbrel include “…improving mobility, range of motion, flexibility and physical function comprising… a mixture of an extract derived from Scutellaria enriched for Free-B-ring flavonoids containing baicalin and an extract derived from Acacia enriched for flavans containing catechin or epicatechin…”
“This new patent validates the uniqueness of Limbrel’s proprietary combination of ingredients which was designed for osteoarthritis patients,” said J.D. Weir, CEO of Primus. “This patent provides an additional layer of protection beyond the existing patents on the individual components. Now no other product can contain Limbrel’s pharmaceutical grade ingredients, particularly at such a high purity and concentration. We are especially proud to have a strong licensing partner with a track record for developing and aggressively defending this kind of robust intellectual property.”
Osteoarthritis is a disease that is caused, in part, by the metabolism of fatty acids, such as arachidonic acid through metabolic inflammatory processes involving cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX) enzymes. The pathology and metabolic aspects of OA involving these enzymatic processes were published in the Journal of Knee Surgery, “Metabolic Pathogenesis of Osteoarthritis” (2006; 19(3):191-197).
Flavocoxid’s composition is responsible for Limbrel’s clinical efficacy through the metabolic dietary management of arachidonic acid enzymatic and oxidative pathways of osteoarthritis (OA). Over 100,000 patients have used Limbrel under the care of Rheumatologists, Orthopedic Surgeons and Pain Management physicians. Limbrel is only available by prescription and is dispensed at retail pharmacies nationwide.
About Primus Pharmaceuticals, Inc.
Primus is the first specialty pharmaceutical company to focus on prescription metabolic products which improve patient quality of life without compromising safety. Primus develops branded prescription drugs and medical foods that are patented and effective in chronic or recurring diseases. The Company’s unique approach is to develop safe prescription products formulated to restore metabolic processes at the disease source rather than focusing on symptoms. Primus promotes to targeted physician specialists and extends its sales coverage and clinical capabilities through strategic partnerships. Primus is privately held and based in Scottsdale, Ariz. www.primusrx.com.
The Company’s brands include: Limbrel® (flavocoxid) www.limbrel.com, Fosteum® (genistein aglycone/citrated zinc bisglycinate/cholecalciferol) www.fosteum.com, Alcortin® A (iodoquinol/hydrocortisone acetate/aloe polysaccharide) www.alcortin-a.com, and Novacort (hydrocortisone acetate/pramoxine HCl) www.novacort.com.
About Limbrel®
Limbrel is the first prescription medical food product developed to safely meet the distinctive nutritional requirements of patients with osteoarthritis. Limbrel contains flavocoxid, a proprietary combination of natural flavonoid ingredients that meet the FDA safety standard of Generally Recognized As Safe (GRAS). Flavonoids are healthful ingredients found in colored vegetables, fruits, cocoa, red wine and green tea. Limbrel restores the body’s normal inflammatory processes through the dual regulation (COX + LOX) of excess arachidonic acid metabolization as well as antioxidant action. Clinical studies have shown Limbrel to be effective in the dietary management of osteoarthritis. Limbrel is manufactured according to FDA current Good Manufacturing Practices (cGMPs). It is only available by prescription. For more information, visit www.limbrel.com.
Contacts
Primus Pharmaceuticals, Inc.
Sylvia Chen, 480-483-1410
No comments:
Post a Comment